Table 3.
Fiber Source/Component | Fiber Fraction | Human Subject Supplementation Groups Baseline and Supplement (Suppl) Study Periods | p-value | ||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Placebo Control | CMC | GA | PSY | Fiber Group Baseline Period | Fiber Group Overall | Period | Fiber Group Supplement Periodb | ||||||
Baseline | Suppl | Baseline | Suppl | Baseline | Suppl | Baseline | Suppl | ||||||
CMC | |||||||||||||
Glucose | SOL | .36(.15) | .39(.10) | .42(.07) | .50(.11) | .38(.18) | .34(.13) | .41(.10) | .41(.11) | .66 | .09 | .36 | .22 |
INS | .77(.20) | .69(.21) | .77(.19)C | .58(.13)d | .76(.14) | .64(.12) | .80(.19) | .64(.14) | .95 | .77 | <.001 | .50 | |
Xylose | SOL | .52(.10) | .49(.12) | .59(.09) | .61(.08) | .58(.10) | .51(.12) | .53(.10) | .52(.24) | .23 | .11 | .35 | .55 |
INS | .77(.19) | .83(.21)A | .72(.27) | .76(.12)A | .79(.15) | .72(.21)A | .73(.29)c | .39(.25)dB | .85 | .004 | .04 | .002 | |
Total | INS | .75(.20) | .67(.21) | .78(.23)C | .59(.17)d | .75(.13) | .59(.20) | .77(.21) | .54(.12) | .96 | .82 | <.001 | .17 |
SOL | .41(.19) | .43(.10) | .45(.20) | .56(.12) | .42(.12) | .40(.15) | .48(.11) | .43(.10) | .78 | .06 | .34 | .09 | |
GA | |||||||||||||
Arabinose | SOL | .93(.11) | .91(.13)A | .99(.07)c | .89(.15)dB | .92(.11) | .94(.10)A | .98(.11) | .92(.10)A | .20 | .89 | .005 | .009 |
Galactose | SOL | .92(.11) | .92(.12)A | .98(.07)c | .89(.14)dB | .91(.11) | .94(.09)A | .97(.10) | .91(.09)B | .21 | .93 | .04 | .01 |
Uronics | SOL | .97(.12) | .94(.08) | .93(.14) | .97(.07) | .94(.13) | .97(.05) | .92(.13) | .92(.06) | .80 | .64 | .61 | .51 |
Total | INS | .59(.24) | .50(.27) | .68(.21)c | .31(.15)d | .64(.13) | .20(.38) | .42(.36) | .21(.44) | .43 | .54 | .004 | .10 |
SOL | .94(.10) | .91(.10) | .97(.04) | .88(.22) | .92(.08) | .95(.07) | .95(.07) | .92(.08) | .45 | .97 | .52 | .07 | |
PSY | |||||||||||||
Xylose | INS | .84(.06)d | .89(.04)c | .88(.04) | .86(.06) | .85(.06) | .87(.05) | .83(.09)C | .87(.06)d | .19 | .80 | .009 | .003 |
Arabinose | INS | .72(.08)d | .79(.05)c | .74(.06) | .76(.06) | .73(.05) | .73(.10) | .73(.06) | .75(.04) | .75 | .75 | .009 | .08 |
Uronics | INS | .89(.19) | .94(.16) | .99(.08) | .89(.06) | .97(.07) | .95(.11) | .92(.10) | .91(.08) | .15 | .67 | .12 | .02 |
Total | INS | .79(.06) | .84(.07) | .83(.05) | .79(.06) | .81(.05) | .79(.06) | .78(.07) | .80(.02) | .20 | .69 | .92 | .003C |
SOL | .18(.11) | .30(.26) | .36(.09) | .47(.21) | .25(.14) | .32(.20) | .15(.13) | .70(.31) | .18 | .26 | .02 | .92 |
Values are means (sds); supplement period means presented are unadjusted for baseline values; bolded values show where the substrate was the same as the fiber that the group ingested.
Because baseline values serve as the reference time point and are coded as 0, these p-values also test the significance of group × period interaction effect.
Values for in vitro degradability of a fiber source component for baseline and supplementation periods within a fiber supplementation group that do not share a superscript within a row differ significantly (p <0.05).
Values for in vitro degradability of a fiber source component in the supplementation period that do not share a superscript within a row differ significantly between fiber supplementation groups (p <0.05).
For this row, none of the comparisons between the values during the supplementation period were significantly different after adjustment for values in the baseline period.